The firm will use the proceeds to develop radiopharmaceuticals, including its lead candidate poised to enter clinical trials next year in small cell lung cancer.
HONG KONG, July 28, 2023 /PRNewswire/ In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical.
/PRNewswire/ DTx Pharma, invested and incubated by Viva BioInnovator (VBI), is a preclinical stage biotechnology company addressing the delivery challenges.